A description of the use of ALK-TKI treatment for patients with ALK positive advanced non-small cell lung cancer, co-authored by Quantify’s Rosa Lauppe and Mathias Lilja, has been published in the Acta Oncologica journal.

Using Swedish national registry data, this study provides a unique overview of all patients treated with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors (ALK-TKI) therapies in Sweden and offers insight into the sequencing strategies used in clinical practice. The results show that most but not all patients are treated according to guidelines and that frontline chemotherapy had been used to a significant extent even with accessibility to ALK-targeted agents.

The full article can be found here: https://www.tandfonline.com/doi/full/10.1080/0284186X.2022.2133972